Methylphenidate (Ritalin, Concerta): Uses, Dosage, and What to Expect

Methylphenidate (brand name: Ritalin, Concerta, Focalin, Daytrana) is a central nervous system stimulant. Methylphenidate primarily blocks the reuptake of dopamine and norepinephrine by binding to their respective transporters (DAT and NET) in the prefrontal cortex and striatum. Unlike amphetamines, methylphenidate does not significantly promote neurotransmitter release — it primarily prevents reuptake of naturally released dopamine and norepinephrine. This increases dopaminergic and noradrenergic signaling in the prefrontal cortex, improving executive function, sustained attention, and impulse control.

• Attention-Deficit/Hyperactivity Disorder (ADHD) in children age 6+ and adults
• Narcolepsy

Common off-label uses:

• Treatment-resistant depression (augmentation)
• Fatigue in cancer and palliative care
• Cognitive enhancement in brain injury
• Apathy in dementia

Immediate-release (Ritalin): 5-10 mg 2-3 times daily, max 60 mg/day. Extended-release (Concerta): 18-36 mg once daily, max 72 mg/day. Other ER formulations (Ritalin LA, Metadate CD) have different dosing. Start low, titrate weekly based on response and side effects. Many patients respond between 0.3-1 mg/kg/day.

Immediate-release: 20-30 minutes, lasts 3-4 hours. Extended-release (Concerta): 30-60 minutes, lasts 10-12 hours. Effects are noticeable from the first dose.

• Decreased appetite and weight loss
• Insomnia (especially if dosed too late)
• Headache
• Stomachache and nausea
• Increased heart rate and blood pressure
• Irritability during wear-off
• Dry mouth

• Cardiovascular events (rare; screen for cardiac conditions before starting)
• Growth suppression in children (monitor height and weight)
• Psychiatric effects (new onset or worsening of tics, psychosis, mania)
• Priapism (rare)
• Peripheral vasculopathy (Raynaud's phenomenon)
• Risk of misuse (lower than amphetamines, but present)

MAOIs are contraindicated (hypertensive crisis). May reduce effectiveness of antihypertensives. Caution with other sympathomimetics. Methylphenidate is not primarily metabolized by CYP450, resulting in fewer drug interactions than many psychiatric medications.

Category C. Limited data. Use only if benefits clearly outweigh risks. No established pattern of malformations.

No physical withdrawal. Can be stopped abruptly, though ADHD symptoms return immediately. Some patients experience rebound fatigue and mood dips for a few days.